{"id":10848,"date":"2023-11-08T01:31:12","date_gmt":"2023-11-08T01:31:12","guid":{"rendered":"https:\/\/infundpros.com\/investment\/ventyx-biosciences-stock-suffering-record-plunge-after-psoriasis-treatment-trial-fails-to-meet-internal-efficacy-target\/"},"modified":"2023-11-08T01:31:13","modified_gmt":"2023-11-08T01:31:13","slug":"ventyx-biosciences-stock-suffering-record-plunge-after-psoriasis-treatment-trial-fails-to-meet-internal-efficacy-target","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=10848","title":{"rendered":"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target"},"content":{"rendered":"
\n

Shares of Ventyx Biosciences Inc.
\n VTYX,
\n -80.62%<\/bg-quote>
\n plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psoriasis and psoriatic arthritis treatments. The stock, which was the biggest decliner listed on major U.S. exchanges ahead of the open, was on track to suffer a record one-day selloff and open in record-low territory. \u201cAlthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis,\u201d the company said in a statement. \u201cAccordingly, we will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately.\u201d Because of the results, the company decided to also terminate the Phase 2 trial of the psoriatic arthritis treatment. The stock has tumbled 57.3% over the past three months through Monday, while the iShares Biotechnology ETF has lost 5.6% and the S&P 500
\n SPX,
\n +0.28%<\/bg-quote>
\n has slipped 3.4%.<\/p>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shares of Ventyx Biosciences Inc. VTYX, -80.62% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not…<\/p>\n","protected":false},"author":1,"featured_media":1240,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":{"0":"post-10848","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investment"},"yoast_head":"\nVentyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target | inFundPros<\/title>\n<meta name=\"description\" content=\"Shares of Ventyx Biosciences Inc. VTYX, -80.62% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=10848\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target | inFundPros\" \/>\n<meta property=\"og:description\" content=\"Shares of Ventyx Biosciences Inc. VTYX, -80.62% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=10848\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-08T01:31:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-08T01:31:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/MW-GP644_MicroS_ZG_20180906154215.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1320\" \/>\n\t<meta property=\"og:image:height\" content=\"742\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=10848#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=10848\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target\",\"datePublished\":\"2023-11-08T01:31:12+00:00\",\"dateModified\":\"2023-11-08T01:31:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=10848\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=10848#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=10848\",\"url\":\"https:\/\/infundpros.com\/?p=10848\",\"name\":\"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-11-08T01:31:12+00:00\",\"dateModified\":\"2023-11-08T01:31:13+00:00\",\"description\":\"Shares of Ventyx Biosciences Inc. VTYX, -80.62% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=10848#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=10848\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=10848#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target | inFundPros","description":"Shares of Ventyx Biosciences Inc. VTYX, -80.62% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=10848","og_locale":"en_US","og_type":"article","og_title":"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target | inFundPros","og_description":"Shares of Ventyx Biosciences Inc. VTYX, -80.62% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to","og_url":"https:\/\/infundpros.com\/?p=10848","og_site_name":"inFundPros","article_published_time":"2023-11-08T01:31:12+00:00","article_modified_time":"2023-11-08T01:31:13+00:00","og_image":[{"width":1320,"height":742,"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/MW-GP644_MicroS_ZG_20180906154215.jpg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=10848#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=10848"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target","datePublished":"2023-11-08T01:31:12+00:00","dateModified":"2023-11-08T01:31:13+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=10848"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Investment"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=10848#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=10848","url":"https:\/\/infundpros.com\/?p=10848","name":"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-11-08T01:31:12+00:00","dateModified":"2023-11-08T01:31:13+00:00","description":"Shares of Ventyx Biosciences Inc. VTYX, -80.62% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=10848#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=10848"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=10848#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target"}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/10848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10848"}],"version-history":[{"count":1,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/10848\/revisions"}],"predecessor-version":[{"id":10849,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/10848\/revisions\/10849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/media\/1240"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}